© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Eton Pharmaceuticals, Inc. (ETON) stock surged +44.26%, trading at $58.86 on NASDAQ, up from the previous close of $40.80. The stock opened at $54.40, fluctuating between $53.01 and $59.69 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | 54.93 | 59.79 | 53.01 | 58.86 | 2.29M |
| Aug 13, 2026 | 42.11 | 43.19 | 40.66 | 40.80 | 626.84K |
| Aug 12, 2026 | 41.99 | 43.18 | 41.18 | 41.58 | 549.84K |
| Aug 11, 2026 | 43.60 | 43.60 | 40.61 | 42.05 | 584.37K |
| Aug 10, 2026 | 44.50 | 45.35 | 43.12 | 43.67 | 368.64K |
| Aug 07, 2026 | 46.09 | 46.60 | 44.55 | 44.60 | 277.12K |
| Aug 06, 2026 | 47.36 | 47.36 | 44.40 | 46.18 | 532.14K |
| Aug 05, 2026 | 47.97 | 48.39 | 45.45 | 45.97 | 388.74K |
| Aug 04, 2026 | 45.09 | 46.11 | 44.99 | 45.83 | 341.77K |
| Aug 03, 2026 | 46.52 | 46.55 | 43.49 | 45.14 | 469.62K |
| Jul 31, 2026 | 49.09 | 49.09 | 46.01 | 46.42 | 484.76K |
| Jul 30, 2026 | 47.08 | 49.21 | 46.75 | 49.03 | 601.88K |
| Jul 29, 2026 | 46.57 | 50.18 | 46.55 | 48.13 | 697.87K |
| Jul 28, 2026 | 43.58 | 47.16 | 42.92 | 46.66 | 890.66K |
| Jul 27, 2026 | 42.73 | 43.84 | 42.06 | 42.31 | 365.38K |
| Jul 24, 2026 | 44.14 | 44.55 | 42.39 | 42.59 | 385.47K |
| Jul 23, 2026 | 43.29 | 44.91 | 42.90 | 44.14 | 571.03K |
| Jul 22, 2026 | 43.32 | 43.93 | 42.70 | 43.58 | 584.14K |
| Jul 21, 2026 | 41.33 | 43.76 | 40.86 | 43.20 | 652.16K |
| Jul 20, 2026 | 42.49 | 42.52 | 40.24 | 41.07 | 739.71K |
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
| Employees | 44 |
| Beta | 0.86 |
| Sales or Revenue | $21.25M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |